Cerity Partners’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $7.39M | Buy |
58,774
+25,413
| +76% | +$3.19M | 0.01% | 649 |
|
|
2025
Q1 | $3.69M | Sell |
33,361
-8,376
| -20% | -$926K | 0.01% | 845 |
|
|
2024
Q4 | $5.29M | Buy |
41,737
+2,713
| +7% | +$344K | 0.01% | 691 |
|
|
2024
Q3 | $4.5M | Buy |
39,024
+11,622
| +42% | +$1.34M | 0.01% | 734 |
|
|
2024
Q2 | $3.77M | Sell |
27,402
-1,354
| -5% | -$186K | 0.01% | 692 |
|
|
2024
Q1 | $3.97M | Buy |
28,756
+24,392
| +559% | +$3.36M | 0.01% | 723 |
|
|
2023
Q4 | $575K | Buy |
+4,364
| New | +$575K | ﹤0.01% | 1207 |
|
|
2023
Q3 | – | Sell |
-4,214
| Closed | -$397K | – | 1604 |
|
|
2023
Q2 | $397K | Buy |
4,214
+365
| +9% | +$34.4K | ﹤0.01% | 1279 |
|
|
2023
Q1 | $390K | Buy |
3,849
+610
| +19% | +$61.7K | ﹤0.01% | 1409 |
|
|
2022
Q4 | $387K | Buy |
3,239
+533
| +20% | +$63.7K | ﹤0.01% | 1051 |
|
|
2022
Q3 | $288K | Sell |
2,706
-202
| -7% | -$21.5K | ﹤0.01% | 910 |
|
|
2022
Q2 | $284K | Buy |
+2,908
| New | +$284K | ﹤0.01% | 927 |
|